ENIS IIIEfficacy and safety of Nelonemdaz (Neu2000) in acute Ischemic Stroke patients (PIII)
A Phase III clinical trial in China to verify safety and efficacy of nelonemdaz in 948 patients with moderate and severe acute stroke receiving thrombolytics within 8 hours after stroke onset.
Participating Hospitals (Department of Neurology): 39 university hospitals, including Tiantan Hospital, Capital Medical University in Beijing.
This trial commenced in September 2020 (first patient enrolled on December 25, 2020).
Total No. of Enrolled Patients
Progress Rate of September 1, 2023